Peyrin-Biroulet, L. Et Al. 2023. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. GASTROENTEROLOGY , vol.165, no.6 , 1443-1457.

Peyrin-Biroulet, L., Allegretti, J. R., Rubin, D. T., Bressler, B., Germinaro, M., Huang, K. (., ... Shipitofsky, N.(2023). Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. GASTROENTEROLOGY , vol.165, no.6, 1443-1457.

Peyrin-Biroulet, Laurent Et Al. "Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study," GASTROENTEROLOGY , vol.165, no.6, 1443-1457, 2023

Peyrin-Biroulet, Laurent Et Al. "Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study." GASTROENTEROLOGY , vol.165, no.6, pp.1443-1457, 2023

Peyrin-Biroulet, L. Et Al. (2023) . "Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study." GASTROENTEROLOGY , vol.165, no.6, pp.1443-1457.

@article{article, author={Laurent Peyrin-Biroulet Et Al. }, title={Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study}, journal={GASTROENTEROLOGY}, year=2023, pages={1443-1457} }